Business Wire

Celltrion’s Subsidiary Acquires Primary Care Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

Share

Celltrion (KRX:068270) announced today that it has signed an agreement to acquire product assets for the Asia Pacific region from Takeda Pharmaceuticals International AG (“Takeda”) in an effort to strengthen its R&D capabilities in the Global Small Molecule Drug sector.

This signing allows Celltrion to acquire Takeda’s Primary Care businesses in the Asia Pacific region and secure rights for patent, trademark, approval and sales of a total of 18 prescription and over-the-counter brands currently available in 9 markets in the region, namely, South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia and Australia. These products grossed a combined sale of approximately $140 million USD (approx. KRW 170 billion) in Fiscal Year 2018 in these markets. These products are expected to be distributed by Celltrion Pharm, a Celltrion affiliate company, in Korea and by Celltrion Healthcare in other AP territories leveraging their distribution and marketing capabilities.

Celltrion agreed to acquire these rights for USD 278.3 million. It will acquire the business through its wholly owned subsidiary in Singapore. Subject to approval from relevant local and/or foreign authorities, Celltrion plans to complete the transaction by the end of the fourth quarter this year.

The acquired product portfolio includes global new drug Nesina, Actos (both for diabetes) and Edarbi (hypertension) and also well-known OTC drugs such as Whituben (cold remedy) and Albothyl (stomatitis). Among them, Nesina and Edarbi are protected through product patents until 2026 and 2027, respectively.

Takeda and Celltrion have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture the portfolio of divested products and supply them to Celltrion. Celltrion plans to receive relevant technology transfer to start local manufacturing at Celltrion Pharma’s cGMP production facilities for some of the key acquired products for sales in local and foreign markets.

Celltrion’s first large-scale M&A deal, this acquisition gives Celltrion a pivotal opportunity to establish a robust presence as a local original drug provider in the Korean market. Demand has been high for treatments for chronic diseases such as diabetes, hypertension and hyperlipidemia in Korea. Despite this trend, multinational pharmaceuticals have constituted a majority of the local supplies. Celltrion hopes to position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.

The deal also provides significant potential for the company’s sustainable growth. Celltrion plans to quickly land these products in the Asia Pacific market, tapping into Takeda’s established brand power for prescription drugs.

Celltrion expects this acquisition to allow the company to mature as a comprehensive global pharmaceutical company, as it adds a powerful small molecule product lineup to its already strong biopharmaceutical pipeline, which includes autoimmune disease and anti-cancer drugs.

The competitive over-the-counter drug brands added through this deal will also help raise Celltrion’s brand awareness among consumers.

Meanwhile, diabetes and hypertension drug markets in the Asia Pacific region were worth KRW 3 trillion and KRW 2.76 trillion1 last year, respectively. The combined market size of these two segments is expected to double to KRW 11 trillion by 2030.

This deal is expected to strengthen Celltrion’s global R&D capability and help spur the development of new drugs and insulin biosimilars. Celltrion will utilize the new drug pipeline to complete its portfolio for diabetes and hypertension treatments. Based on these efforts, Celltrion will continue to tap the U.S. and global procurement markets to provide high-quality and cost-effective pharmaceuticals around the world.

Celltrion CEO Kee Woo Sung said, ”With 17 million diabetes and hypertension patients in Korea alone and more than 60% of the elderly population have three or more chronic diseases, the market for chronic disease drugs is becoming more important. By acquiring the rights for a selection of Takeda’s products in Asia Pacific, Celltrion will be able to localize essential drugs for diabetes and hypertension, for which many local patients had to depend on imported drugs. This transaction will help us contribute to improved public healthcare and more resilient National Health finance in this super-aged society. Celltrion will take a big step to become a comprehensive global biopharmaceutical company.”

About Celltrion, Inc

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in the research, development and manufacture of small molecules, biosimilars and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, the world’s first mAb biosimilar approved from regulatory agencies in developed countries. For more information, visit www.celltrion.com.


1. IQVIA, 2019, Market size of diabetes treatments in 8 APAC countries and hypertension treatments in 6 APAC countries

Contact information

Celltrion, Inc.
Eunyoung Lee, +82 32 850 4384
Eunyoung.lee1@celltrion.com
Or
Tae-Gyun Kim, +82 32 850 5136
taegyun.kim@celltrion.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taulia’s Darcy Douglas Named One of the Top Women in Supply Chain23.9.2020 19:30:00 CESTPress release

Taulia, the leader in working capital technology solutions, has today announced Darcy Douglas, VP of Professional Services, has been listed as a recipient of Supply & Demand Chain Executive’s first Women in Supply Chain award. The award recognizes female leaders in the supply chain industry who have demonstrated a commitment to excellence in their respective roles and also supporting other women to develop their careers and skills. Darcy has been at Taulia for ten years and her leadership has helped the company grow from a small start-up to an established market leader in the supply chain finance industry. During her time at Taulia, Darcy has spearheaded the creation of three leadership and professional development programs that help Taulians boost their skills and enhance their careers. Specifically, Darcy created the Leadership Initiative for Taulia (LIFT) program for women, which includes a mentoring program, education classes, and other activities, to inspire development and leader

DC Secretary Announces Proposed Amendments to DC Rules23.9.2020 17:22:00 CESTPress release

DC Administration Services, Inc., in its capacity as DC Secretary, has today published to the DC website proposed amendments to the Deliverable Obligation and External Review provisions of the DC Rules. Any Eligible Market Participant may provide comments on the proposed amendments to the DC Rules until 5:00pm EDT Tuesday, September 29, 2020. The proposed amendments to the DC Rules, together with additional information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/. Other inquires may be directed to Mark Ferraris at mark.ferraris@citadelspv.com View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005724/en/Contact information Mark Ferraris mark.ferraris@citadelspv.com

MIRIS: Green Growth in the Midst of a Pandemic23.9.2020 16:19:00 CESTPress release

In March 2020, also Norway ran out of infection control equipment. In this critical phase, MIRIS, a top tier technology green real estate company, initiated a collaboration with China Development Integration Limited (CDIL), a major EPC integration corporation in the Silk Road initiative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005669/en/ From left to right: Henrik Berg Klemmetsen, Magdalena Urbanik, Danny Wong, Andy Lai , Davis Chiu Xinwen Chang and Jan Gunnar Mathisen. Frame: Edmund Amir. (Photo: Business Wire) The two companies have a relationship with regards to building a large-scale smart city in Europe, and MIRIS realized the possibility of a cooperation with CDIL and its resources to ensure supply of high quality infection control equipment. Together they fulfilled significant contracts regarding infection control equipment for several countries, including Norway. In a market described as the "Wild West",

CORRECTING and REPLACING S ES Becomes Microsoft Azure Orbital Founding Connectivity Partner23.9.2020 15:38:00 CESTPress release

Second paragraph of release dated September 22, 2020 should read: The first MEO and Earth Observation gateways will be located in the United States; in Phoenix, Arizona and Quincy, Washington respectively.(instead of ... located in Phoenix, Arizona, United States and Quincy, Western Australia respectively). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005927/en/ SES Becomes Microsoft Azure Orbital Founding Connectivity Partner (Photo: Business Wire) The updated release reads: SES BECOMES MICROSOFT AZURE ORBITAL FOUNDING CONNECTIVITY PARTNER SES’s proven low-latency MEO managed services to be part of Microsoft’s new multi-orbit satellite connectivity integrated with Azure, promising optimized cloud application performance for O3b mPOWER customers SES today announced it has joined as the medium Earth orbit (MEO) connectivity partner for Microsoft Azure Orbital, Microsoft’s new managed service enabling network operators

CORRECTING and REPLACING SES Advances Digital Transformation with Cloud-First Strategy, Expanded Agreement23.9.2020 15:36:00 CESTPress release

Eighth paragraph of release dated September 22, 2020 should read: The two companies will make joint investments in Azure Orbital ground stations for the MEO and Earth Observation segments that SES will deploy and manage based on its industry expertise, with the first Earth Observation gateway being located at Quincy, Washington in the United States. (instead of ... with the first Earth Observation gateway being located at Quincy, Western Australia.). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005930/en/ SES Advances Digital Transformation with Cloud-First Strategy, Expanded Agreement (Photo: Business Wire) The updated release reads: SES ADVANCES DIGITAL TRANSFORMATION WITH CLOUD-FIRST STRATEGY, EXPANDED AGREEMENT Multi-year agreement with Microsoft includes Azure Orbital integration, SES’s expanded use of Azure and joint development of new video and data connectivity services SES today announced plans to significan

Former World Head of State to Address Attendees at Everbridge’s COVID-19: Road to Recovery (R2R) Symposium, Joining Dr. Anthony Fauci, Sir Richard Branson, and Dr. Sanjay Gupta as Keynotes, October 14-15, 202023.9.2020 15:29:00 CESTPress release

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that a former World Head of State will address attendees to its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid the COVID-19 pandemic. The addition of a former World Head of State represents the latest in a top-tier line-up of leading experts and C-level executives who will share their perspectives on best practices for the safe reintegration of people back to work, campuses and public spaces; the restoration of revenue-generating operations; and the protection of citizens on a countrywide scale amid the coronavirus pandemic. Keynote speakers include presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci, Virgin Group Founder Sir Richard Branson, and renowned neurosurgeon and CNN Chie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom